Loading…
S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells
Cell viability following short (1 h) contact with paclitaxel or docetaxel was assayed using synchronised HeLa cells. Docetaxel proved almost totally lethal against S-phase cells. Its toxicity was only partial against cells in mitosis, and declined to a minimum with progression to G1. For paclitaxel,...
Saved in:
Published in: | British journal of cancer 1995-06, Vol.71 (6), p.1194-1198 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c446t-8b2a206454a869be84377edeb4b64050a688fe88196f11ea9c604e45a910c8773 |
---|---|
cites | |
container_end_page | 1198 |
container_issue | 6 |
container_start_page | 1194 |
container_title | British journal of cancer |
container_volume | 71 |
creator | Hennequin, C Giocanti, N Favaudon, V |
description | Cell viability following short (1 h) contact with paclitaxel or docetaxel was assayed using synchronised HeLa cells. Docetaxel proved almost totally lethal against S-phase cells. Its toxicity was only partial against cells in mitosis, and declined to a minimum with progression to G1. For paclitaxel, cytotoxicity increased with progression through S and G2, peaked at the time of mitosis, and decreased thereafter. Maximum resistance to paclitaxel was in early S. Although lethal, brief exposure to docetaxel in S-phase did not delay progression through S and G2. Gross damage was detectable immediately after mitosis, with dysfunction in cytokinesis and accumulation of multinucleated, non-viable cells. Arrest of cells at prometaphase required continuous contact with lethal amounts of docetaxel or reintroduction of drug shortly before mitosis following pulse-chase treatment in mid-S-phase. Paclitaxel at moderate doses presumably acts mostly via damage to the mitotic spindle. In contrast, the available data suggest that docetaxel primarily targets centrosome organisation, leading to abortive mitosis and cell death. |
doi_str_mv | 10.1038/bjc.1995.232 |
format | article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2033844</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>7779710</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-8b2a206454a869be84377edeb4b64050a688fe88196f11ea9c604e45a910c8773</originalsourceid><addsrcrecordid>eNptkE1LAzEQhoMoWj9uXoUcPCi4dbKb3SQXQcQvKHjw4xqy6WybumZLsor990ZbioKnYXifeQceQg4ZDBkU8rye2SFTqhzmRb5BBqws8ozJXGySAQCIDFQOO2Q3xllaFUixTbaFEEowGJCXx2w-NRFpnKN1jbOuX9CuoRbblr66tnV-QusFHXcWe_OJLT15Mp9djwFPqfM0Lrydhs67iGN6hyPzcxn3yVZj2ogHq7lHnm-un67ustHD7f3V5SiznFd9Juvc5FDxkhtZqRolL4TAMda8rjiUYCopG5SSqaphDI2yFXDkpVEMrBSi2CMXy975e_2GY4u-D6bV8-DeTFjozjj9N_Fuqifdh86hKCTnqeBsWWBDF2PAZn3LQH_r1Umv_tark96EH_3-t4ZXPlN-vMpNtKZtgvHWxTVWlLysQCUsW2IxJX6CQc-69-CTqf_ffgFeqJIu</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells</title><source>PubMed Central</source><creator>Hennequin, C ; Giocanti, N ; Favaudon, V</creator><creatorcontrib>Hennequin, C ; Giocanti, N ; Favaudon, V</creatorcontrib><description>Cell viability following short (1 h) contact with paclitaxel or docetaxel was assayed using synchronised HeLa cells. Docetaxel proved almost totally lethal against S-phase cells. Its toxicity was only partial against cells in mitosis, and declined to a minimum with progression to G1. For paclitaxel, cytotoxicity increased with progression through S and G2, peaked at the time of mitosis, and decreased thereafter. Maximum resistance to paclitaxel was in early S. Although lethal, brief exposure to docetaxel in S-phase did not delay progression through S and G2. Gross damage was detectable immediately after mitosis, with dysfunction in cytokinesis and accumulation of multinucleated, non-viable cells. Arrest of cells at prometaphase required continuous contact with lethal amounts of docetaxel or reintroduction of drug shortly before mitosis following pulse-chase treatment in mid-S-phase. Paclitaxel at moderate doses presumably acts mostly via damage to the mitotic spindle. In contrast, the available data suggest that docetaxel primarily targets centrosome organisation, leading to abortive mitosis and cell death.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1995.232</identifier><identifier>PMID: 7779710</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Antineoplastic agents ; Antineoplastic Agents, Phytogenic - toxicity ; Biological and medical sciences ; Biological Transport ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Cell Cycle - drug effects ; Cell Division - drug effects ; Cell Survival - drug effects ; Docetaxel ; Drug Resistance ; Epidemiology ; experimental-oncology ; General aspects ; HeLa Cells ; Humans ; Kinetics ; Medical sciences ; Molecular Medicine ; Oncology ; Paclitaxel - analogs & derivatives ; Paclitaxel - metabolism ; Paclitaxel - toxicity ; Pharmacology. Drug treatments ; S Phase ; Taxoids ; Time Factors ; Tritium ; Tumor Stem Cell Assay</subject><ispartof>British journal of cancer, 1995-06, Vol.71 (6), p.1194-1198</ispartof><rights>Cancer Research Campaign 1995</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-8b2a206454a869be84377edeb4b64050a688fe88196f11ea9c604e45a910c8773</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033844/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033844/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3545609$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7779710$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hennequin, C</creatorcontrib><creatorcontrib>Giocanti, N</creatorcontrib><creatorcontrib>Favaudon, V</creatorcontrib><title>S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Cell viability following short (1 h) contact with paclitaxel or docetaxel was assayed using synchronised HeLa cells. Docetaxel proved almost totally lethal against S-phase cells. Its toxicity was only partial against cells in mitosis, and declined to a minimum with progression to G1. For paclitaxel, cytotoxicity increased with progression through S and G2, peaked at the time of mitosis, and decreased thereafter. Maximum resistance to paclitaxel was in early S. Although lethal, brief exposure to docetaxel in S-phase did not delay progression through S and G2. Gross damage was detectable immediately after mitosis, with dysfunction in cytokinesis and accumulation of multinucleated, non-viable cells. Arrest of cells at prometaphase required continuous contact with lethal amounts of docetaxel or reintroduction of drug shortly before mitosis following pulse-chase treatment in mid-S-phase. Paclitaxel at moderate doses presumably acts mostly via damage to the mitotic spindle. In contrast, the available data suggest that docetaxel primarily targets centrosome organisation, leading to abortive mitosis and cell death.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Phytogenic - toxicity</subject><subject>Biological and medical sciences</subject><subject>Biological Transport</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Cell Cycle - drug effects</subject><subject>Cell Division - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Docetaxel</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>experimental-oncology</subject><subject>General aspects</subject><subject>HeLa Cells</subject><subject>Humans</subject><subject>Kinetics</subject><subject>Medical sciences</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Paclitaxel - analogs & derivatives</subject><subject>Paclitaxel - metabolism</subject><subject>Paclitaxel - toxicity</subject><subject>Pharmacology. Drug treatments</subject><subject>S Phase</subject><subject>Taxoids</subject><subject>Time Factors</subject><subject>Tritium</subject><subject>Tumor Stem Cell Assay</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><recordid>eNptkE1LAzEQhoMoWj9uXoUcPCi4dbKb3SQXQcQvKHjw4xqy6WybumZLsor990ZbioKnYXifeQceQg4ZDBkU8rye2SFTqhzmRb5BBqws8ozJXGySAQCIDFQOO2Q3xllaFUixTbaFEEowGJCXx2w-NRFpnKN1jbOuX9CuoRbblr66tnV-QusFHXcWe_OJLT15Mp9djwFPqfM0Lrydhs67iGN6hyPzcxn3yVZj2ogHq7lHnm-un67ustHD7f3V5SiznFd9Juvc5FDxkhtZqRolL4TAMda8rjiUYCopG5SSqaphDI2yFXDkpVEMrBSi2CMXy975e_2GY4u-D6bV8-DeTFjozjj9N_Fuqifdh86hKCTnqeBsWWBDF2PAZn3LQH_r1Umv_tark96EH_3-t4ZXPlN-vMpNtKZtgvHWxTVWlLysQCUsW2IxJX6CQc-69-CTqf_ffgFeqJIu</recordid><startdate>19950601</startdate><enddate>19950601</enddate><creator>Hennequin, C</creator><creator>Giocanti, N</creator><creator>Favaudon, V</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>19950601</creationdate><title>S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells</title><author>Hennequin, C ; Giocanti, N ; Favaudon, V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-8b2a206454a869be84377edeb4b64050a688fe88196f11ea9c604e45a910c8773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Phytogenic - toxicity</topic><topic>Biological and medical sciences</topic><topic>Biological Transport</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Cell Cycle - drug effects</topic><topic>Cell Division - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Docetaxel</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>experimental-oncology</topic><topic>General aspects</topic><topic>HeLa Cells</topic><topic>Humans</topic><topic>Kinetics</topic><topic>Medical sciences</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Paclitaxel - analogs & derivatives</topic><topic>Paclitaxel - metabolism</topic><topic>Paclitaxel - toxicity</topic><topic>Pharmacology. Drug treatments</topic><topic>S Phase</topic><topic>Taxoids</topic><topic>Time Factors</topic><topic>Tritium</topic><topic>Tumor Stem Cell Assay</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hennequin, C</creatorcontrib><creatorcontrib>Giocanti, N</creatorcontrib><creatorcontrib>Favaudon, V</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hennequin, C</au><au>Giocanti, N</au><au>Favaudon, V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1995-06-01</date><risdate>1995</risdate><volume>71</volume><issue>6</issue><spage>1194</spage><epage>1198</epage><pages>1194-1198</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Cell viability following short (1 h) contact with paclitaxel or docetaxel was assayed using synchronised HeLa cells. Docetaxel proved almost totally lethal against S-phase cells. Its toxicity was only partial against cells in mitosis, and declined to a minimum with progression to G1. For paclitaxel, cytotoxicity increased with progression through S and G2, peaked at the time of mitosis, and decreased thereafter. Maximum resistance to paclitaxel was in early S. Although lethal, brief exposure to docetaxel in S-phase did not delay progression through S and G2. Gross damage was detectable immediately after mitosis, with dysfunction in cytokinesis and accumulation of multinucleated, non-viable cells. Arrest of cells at prometaphase required continuous contact with lethal amounts of docetaxel or reintroduction of drug shortly before mitosis following pulse-chase treatment in mid-S-phase. Paclitaxel at moderate doses presumably acts mostly via damage to the mitotic spindle. In contrast, the available data suggest that docetaxel primarily targets centrosome organisation, leading to abortive mitosis and cell death.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>7779710</pmid><doi>10.1038/bjc.1995.232</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-0920 |
ispartof | British journal of cancer, 1995-06, Vol.71 (6), p.1194-1198 |
issn | 0007-0920 1532-1827 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2033844 |
source | PubMed Central |
subjects | Antineoplastic agents Antineoplastic Agents, Phytogenic - toxicity Biological and medical sciences Biological Transport Biomedical and Life Sciences Biomedicine Cancer Research Cell Cycle - drug effects Cell Division - drug effects Cell Survival - drug effects Docetaxel Drug Resistance Epidemiology experimental-oncology General aspects HeLa Cells Humans Kinetics Medical sciences Molecular Medicine Oncology Paclitaxel - analogs & derivatives Paclitaxel - metabolism Paclitaxel - toxicity Pharmacology. Drug treatments S Phase Taxoids Time Factors Tritium Tumor Stem Cell Assay |
title | S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T07%3A34%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=S-phase%20specificity%20of%20cell%20killing%20by%20docetaxel%20(Taxotere)%20in%20synchronised%20HeLa%20cells&rft.jtitle=British%20journal%20of%20cancer&rft.au=Hennequin,%20C&rft.date=1995-06-01&rft.volume=71&rft.issue=6&rft.spage=1194&rft.epage=1198&rft.pages=1194-1198&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1995.232&rft_dat=%3Cpubmed_cross%3E7779710%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c446t-8b2a206454a869be84377edeb4b64050a688fe88196f11ea9c604e45a910c8773%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/7779710&rfr_iscdi=true |